How do you manage adjuvant therapy for patients with locally advanced ER positive breast cancer with no response to neoadjuvant endocrine therapy?
Assuming cytotoxic chemotherapy is given, would you still then proceed with adjuvant endocrine therapy? Would you switch agents or classes of endocrine therapy given the lack of response in the neoadjuvant setting?
Answer from: Medical Oncologist at Academic Institution
For patients with ER+ locally advanced disease and no response to neoadjuvant chemotherapy (assuming an optimal chemo regimen was given -anthracycline and taxane based, my preferred regimen in this setting would be AC dose dense X4 with pegfligrastim followed by paclitaxel weekly X1...